International Law Office
Trade Negotiators Seek Comment on Elimination of Pharmaceutical Import Duties
April 23, 2010
Over 9,000 pharmaceutical and chemical intermediates enjoy duty free treatment under the customs regime of the United States and other countries that participate in the World Trade Organization Pharmaceutical Agreement. The Office of the U.S. Trade Representative is seeking public comment on the possible expansion of the list of products subject to this reciprocal duty free treatment (comments were due by April 9, 2010).
This Sidley Update was republished by ILO in its Trade & Customs Newsletter.
Capabilities
Suggested News & Insights
Sidley Ranked in Chambers Greater China Region 2026January 15, 2026Key Takeaways from the European Commission’s New Foreign Subsidies Regulation GuidelinesJanuary 14, 2026Two Sidley International Arbitration Cases Recognized on Law360’s “5 International Arbitration Cases to Watch in 2026”January 13, 2026Sidley Advises on Market-Defining Cross-Border India Matters in 2025January 12, 2026The Comprehensive Outbound Investment National Security Act of 2025 Updates the U.S. Outbound Investment Regime: Key TakeawaysJanuary 8, 2026Treasury Clarifies Outbound Investment Regulations with New FAQs on Publicly Traded Securities and the COINS ActJanuary 8, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory